SCHEMBL19808903

SCHEMBL19808903

COC(=O)c1ccc(Oc2ccc(OC)cc2C(C)Br)nc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.45
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ P2RX3 P56373 2/20 0.41
▸ MAPK1 P28482 2/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ LIPE Q05469 1/20 0.40
▸ HPGDS O60760 1/20 0.40
▸ KDM4E B2RXH2 2/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ P2RX2 Q9UBL9 1/20 0.39
▸ ACACB O00763 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ BLM P54132 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ CYP11B1 P15538 1/20 0.38
▸ CYP11B2 P19099 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19808916 0.87 MAPK1 (0.42) LMNAP2RX3MAPK1KDM4EL3MBTL1
SCHEMBL19808863 0.86 P2RX3 (0.45) LMNAP2RX3MAPK1KMT2AKDM4E
SCHEMBL19808889 0.86 LMNA (0.42) LMNAP2RX3MAPK1LIPEKDM4E
SCHEMBL19808857 0.84 LMNA (0.46) LMNACA1CA2P2RX3MAPK1
SCHEMBL19808831 0.84 LMNA (0.56) LMNAMAPK1KMT2ALIPEKDM4E
SCHEMBL19808802 0.84 HRH3 (0.42) LMNAP2RX3MAPK1KDM4EL3MBTL1
SCHEMBL19808908 0.81 ACACB (0.49) LMNACA1CA2MAPK1KMT2A
SCHEMBL19808813 0.80 LMNA (0.47) LMNACA1CA2MAPK1KMT2A
SCHEMBL19808893 0.75 HPGD (0.41) LMNAKMT2A
SCHEMBL19808874 0.74 MAPT (0.47) P2RX3L3MBTL1ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3275881-B1 COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF SHENYANG SUNSHINE PHARMACEUTICAL CO LTD (CN) 2021-08-04 — — EP disclosed
US-10100051-B2 Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. (CN) 2018-10-16 — — US disclosed
US-20180118739-A1 COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROARYLOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD. (CN) 2018-05-03 — — US disclosed
EP-3275881-A1 COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF Shenyang Sunshine Pharmaceutical Co., Ltd. (CN) 2018-01-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180118739-A1 COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROARYLOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF HIF1AN, EGLN3, EGLN2 LMNA 2733/4885CA1 4243/4885CA2 2708/4885
US-10100051-B2 Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof HIF1AN, EGLN3, EGLN2 LMNA 2733/4885CA1 4243/4885CA2 2708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback